Clinical trial
Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or…
NCT00387530 · University of California, San Diego, Other · Withdrawn
Key facts
| NCT number | NCT00387530 |
|---|---|
| Title | Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer |
| Official title | A Phase II Study of Phenylbutyrate and Valganciclovir in Epstein-Barr Virus Positive Tumors |
| Lead sponsor | University of California, San Diego, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer, Head and Neck Cancer, Lymphoma, Lymphoproliferative Disorder |
| Intervention type | Drug, Genetic, Procedure |
| Interventions | oral sodium phenylbutyrate, valganciclovir, polymerase chain reaction, protein expression analysis, biopsy |
| Enrollment | 0 |
| Start date | May 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Oct 13, 2006 |
| Last update posted | Aug 2, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: